Educationcme-utilities.com/mailshotcme/IACH/CVs/Kenet CV-reg-Apr2018.pdf · development of new...

CURRICULUM VITAE Name: Gili Kenet

I.D. 5643188-5

Date and place of birth: May 13, 1960, Tel-Aviv, Israel

Marital status: Married, 3 children

Place of work: Sheba Medical Center, Tel-Hashomer

Phone: 03-5302409/2120

Cellular: 052-666-6385

Email: [email protected]; [email protected]

Faculty: Medicine

Department: Hematology

Home address: 13 Mevo Tofach St., Kiryat Savionim, Yahud, Israel

Zahal military service: 1978-1980 - Intelligence force

Education 1980 - 1987 Hadassah Medical School, Hebrew University, Jerusalem 1983 Bachelor of Science in Basic Life Sciences 1986 Elective internship in Montreal Children's Hospital during exchange program

for outstanding students 1988 MD diploma Doctoral thesis: Delayed Visual Maturation

Supervisors: Amir N., Pediatric Neurologist, Bikur Holim Hospital, Jerusalem. Peer J., Pediatric Ophthalmology, Hadassah Ein-Kerem, Jerusalem

Academic Experience Sept. 90 - Dec. 92 Training with Prof. G. Zaijcek, Head of Medical Computer Unit and Oncology researcher, Hadassah Ein-Kerem Hospital, Jerusalem Research subject: Streaming liver cells Aug. 90 – 1993 Clinical research with autologous cord blood transfusion. Pediatric department and Hematology Department The E. Wolfson Medical Center, Israel 1992 Instructor in Pediatrics Tel Aviv University, Sackler School of Medicine, Israel 1994 Instructor in Hematology, Tel Aviv University, Sackler School of Medicine, Israel

Gili Kenet, MD. April 2018

2

2001 - 2005 Lecturer in Hematology, Tel Aviv University, Sackler School of Medicine, Israel 2006 – 2010 Senior Lecturer, Hematology, Tel-Aviv University 2010 – 2014 Associate Professor, Hematology, Tel-Aviv University Since 2014 Full Clinical Professor Hematology, Tel Aviv University 2014 – 2016 Head of Hematology Faculty, Tel Aviv University

Clinical Experience March 87 - May 88 Internship - The E. Wolfson Medical Center

June 88 – Dec. 92 Division of Pediatrics, E. Wolfson Medical Center

Jan. 93 - June 95 Fellowship - Institute of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer

Since June 1995 Specialist in Pediatric Hemato-Oncology.

Responsible for Pediatric Thrombosis and Hemostasis Service, The Chaim Sheba Medical Center, Tel-Hashomer, and the National Hemophilia Center, Tel-Hashomer

June 2001 Director, Pediatric Coagulation Service, The National Hemophilia Center, Tel-Hashomer

Since Sept. 2007 Director, Thrombosis Unit

Since Nov. 2012 Acting Head - National Hemophilia Center

Since July 2013 Director, National Hemophilia Center and Thrombosis Institute, Sheba Medical Center, Tel Hashomer

Since Nov. 2017 Head of Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

International and Domestic Scientific Activities 2008 – 2011 SSC of ISTH Chair, Pediatric Perinatal Hemostasis

2010 – 2014 Chair Israeli Society of Thrombosis and Hemostasis

2014 – 2017 CiTH Congress organizer and Chair

Since 2015 F1000 Section Head, Hematology

Since 2015 SSC of ISTH Co-Chair: factor VIII and factor IX - RBD

Since 2016 PEDNET Hemophilia International Foundation - Board of Directors

Scientific Journals

2006 Acta Hematologica Guest Editor Special Issues

2011 Seminars in Thrombosis & Hemostasis - Editorial Board


3

Since 2011 Pediatric new oral anticoagulant multicenter studies - International PI

2013 Seminars Perinatology - Editorial Board

2016 Thromb Research - Editorial Board

2017 BCMD - Editorial Board

Last Congresses participation, 2016 – 2018:

EAHAD, Malmo, Sweden (February) Invited Lecture

SSC, Montpelier, France (May) Invited Lecture

WFH, Orlando, FL, USA (July) Invited Lecture

CiTH, Moscow, USSR Organizing Committee

Congress chair, speaker

EAHAD, Paris, France (February) Invited Lecture

WHITH, Barcelona, Spain Organizing Committee

Chair, oral abstract

EHA, Madrid, Spain (June) Invited speaker

ISTH Berlin, Germany (July) Organizing Committee

Chair, Invited speaker, Oral abstract

ISTH Education Symposia, Bangkok (Nov.) Invited Lecture

GTH 2018, Vienna, Austria (Feb) Invited Lecture

HRSU, Toronto, Canada (March) Co-Chair, "Non-Factor therapies"

IACH, Paris, France (Sept) Invited Speaker

Membership in professional societies Since 1987 Israel Medical Association

Since 1987 Israel Society of Clinical Pediatrics

Since 1994 Israel Society of Hematology and Blood Transfusion

Since 1995 Israel Society of Pediatric Hematology and Oncology

Since 1996 Director- Israeli Pediatric Thrombophilia registry

Since 1998 Israel Society of Thrombosis and Haemostasis

Since 1999 World Federation of Hemophilia

Since 2001 American Society of Hematology

Since 2001 International Society of Thrombosis and Hemostasis (ISTH)


4

MD students supervised by candidate Year Name of student Title of Thesis Institution

2003-

2004

Haim Rapaport Blood clot formation and stability as tested by thromboelastography – TEG

Tel Aviv

University

2004 Arik Steinvil Cone and plate(let) analyzer as a predictor for blood loss after cardiopulmonary bypass

Tel Aviv

University

2004 Yael Levi Shraga

Assessment of platelet function in neonates

using cone and platelet analyzer (CPA)

Tel Aviv

University

2005 Tal Tirosh-Vagner

Testing platelet function under flow condition

by cone and plate(let) analyzer and clot

formation and lysis by rotation thromboelastography in children undergoing cardiopulmonary bypass

Tel Aviv

University

2007 Haya Schwartz-Ganor

Prediction of heparin induced

thrombocytopenia by the 4T score

Tel Aviv

University

2008 Naomi Rozenzweig

Assessment of surfactant impact upon

platelet function and coagulation - a possible mechanism for pulmonary hemorrhage in neonates

Tel Aviv

University

2009 Rakefet Sidlik Fibrinolysis induction and assessment using "ROTEM"- thromboelastogram

Tel Aviv

University

2013 Noa Gal Bridging therapy in patients treated by anticoagulants Tel Aviv

University

2014 Na'ama Schwartz

ADAMTS13 and VWF-Ag in pre-term and

term neonates

Tel Aviv

University

2014 Tal Sadeh The impact of surfactant upon platelet aggregation and activation in healthy term and preterm neonates

Tel Aviv

University

2015 Sara Malkiel Basic research project (for Pediatrics

fellowship, Sheba Medical Center)

Thrombin generation in multiple myeloma patients: potential associations with disease, therapy and incidence of thromboembolic complications

Tel Aviv

University

2015 Yael Goldstein Basic research project (for Pediatrics fellowship, Sheba Medical Center) Heparin induced thrombocytopenia in pediatric patients

Tel Aviv University

M.A./M.Sc. students 2012 Shirly Azar Avivi - Tel Aviv University

Development of a laboratory method for planning personalized combined medication therapy for hemophilia patients with inhibitors aimed at achieving


5

effective hemostasis Grants 2005 The Israeli Cancer Association - grant for national multi-center

study of central venous lines occlusive complications with Dr. Shoshana Vilk-Revel

PI-Co 90,000 ILS

2010 The Tony and Robert Singer foundation of Cancer Research Grant: Study of the potential effect of recombinant activated factor VII (rFVIIa) on endothelial cells tight junctions and vessel wall permeability

PI 32,000 ILS

2010 The Tel Aviv University Research Authority grant from the Claire and Amedee Maratier lnstitute for the Study of Visual Disorders and Blindness: Evaluation of the effect of thrombin and Activated Protein C (APC) on the structure of tight junctions and permeability of microvascular endothelium

PI-Co 10,000 ILS

2012 The Tel Aviv University Research Authority grant from the Meirbaum foundation: Development of a laboratory method for planning personalized combined medication therapy for hemophilia patients with inhibitors aimed at achieving effective hemostasis

PI 37,000 ILS

2012 Bayer Health Care Hematology Conference Research and Development in Hemophilia Poster Award: Can thrombin generation be used to monitor hemostasis? Ex vivo “Mini- PK” studies in people with Hemophilia A and inhibitors

PI-Co 3,000 EUR

2013 BPL - Beyond the Bethesda assay- towards individualized FVIII therapy of inhibitor patients

PI 100,000 EUR

2014 The Tel Aviv University Research Authority grant from the Meirbaum foundation: Towards individualized interpretation of inhibitor patients' profiles: application of epitope mapping and development of new assays

PI 38,000 ILS

2015 Baxter: Personalized therapy for hemophilia patients with inhibitors

PI 100,000 USD

2016 Pfizer: Therapy tailoring for severe Hemophilia B patients with inhibitors – a thrombin generation/thromboelastography guided study. With Dr. Tami Livnat, Co-Investigator

PI 52,000 EUR

2016 Pfizer: Application of attention destruction techniques during factor concentrates infusion to children with Hemophilia. With Dr. Gabi Golan, Co-Investigator

PI 36,800 USD

2016 Bayer: FVIII neutralization in inhibitor plasma. With Dr. Tami Livnat, Co-Investigator

PI 55,000 USD

Awards


6

1984 - 1986 Prizes for Excellency in graduate years

1993 The Stanley Levin foundation research award of the Society of Clinical Pediatrics

2013, 2014 Thrombosis research certificate of outstanding contribution in reviewing

2014

Most popular article in 2012/2013 awarded by Thieme Publishers: Kenet G et al: Impact of persistant APLA on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analyzis. Seminars in Thrombosis and Hemostasis 37(7): 802-9; Oct 2011

LIST OF SCIENTIFIC PUBLICATIONS ORIGINAL ARTICLES

1. Ballin A, Kenet G, Tamany H, Rechavi G, Chividalli Y, Burstein Z, Tauber M. Nussinovitch D, Meytes D. Infantile idiopathic thrombocytopenic purpura. Ped Hematol Oncol 7:323-328, 1990

2. Lishner M, Kenet G, Lalkin A, Yarkoni S, Ben-Bassat I, Fejgin M, Rechavi G, Amiel A. Fluorescent in situ hybridization for the detection of t(8:14) in Burkitt's lymphoma. Acta-Haematol 90:186-189, 1993

3. Mandel M, Toren A, Kende G, Neumann Y, Kenet G, Rechavi G. Familial clustering of malignant germ cell tumors and Langerhans' histiocytosis. Cancer 73:1980-1983, 1994

4. Ballin A, Kenet G, Gutman R, Samra Z, Zakut H, Meytes D. Autologous cord blood transfusion. Acta-Paediatr 83:700-703, 1994

5. Kende G, Toren A, Ben-Bassat I, Mandel M, Neumann Y, Kenet G, Rechavi G. Familial congenital amegakaryocytic thrombocytopenia occurring in females only. Int J Ped Hematol Oncol 2:35-37, 1995

6. Ballin A, Kenet G, Senetzky J, Amzel S. Cervical lymphadenopathy as a sign of atopy in childhood. J Allergy Clin Immunol 96:164-165, 1995

7. Gilad E, Paret G, Katz M, Vardi A, Kenet G, Barzilay Z. Plain radiography for diagnosis of gastrointestinal perforation in immune compromised children -- is it enough? Med Pediatric Oncol 25:470-472, 1995

8. Ballin A, Arbel E, Kenet G, Berar M, Kohelet D, Tanay A, Zakut H, Meytes D. Autologous umbilical cord blood transfusion. Arch Dis Child Fetal Neonatal Ed 73:181-183, 1995

9. Toren A, Sharon N, Mandel M. Neumann Y, Kenet G, Kaplinsky C, Dor J, Rechavi G. Two embryonal cancers after in vitro fertilization. Cancer 76:2372-2374, 1995

10. Inbal A, Kenet G, Zivelin A, Yermiyahu T, Bronstein T, Sheinfeld T, Tamari H, Gitel S, Eshel G, Duchemin J, Aiach M, Seligsohn U. Purpura fulminans induced by disseminated intravascular coagulation following infection in two unrelated children with double heterozygosity for factor V leiden and Protein S deficiency. Thromb Haemost


7

77:1086-1089, 1997

11. Kenet G, Lubetsky A, shenkman B, Tamari I, Darkik R, Rechavi G, Barzilai A, Martinovitz U, Savion N, Varon D. Core and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 101:255-259, 1998.

12. Kaplinsky C, Kenet G, Seligsohn U, Rechavi G. Association between hyperflexibility of the thumb and an unexplained bleeding tendency: is it a rule of thumb? Br J Haematol 101:260-263, 1998.

13. Cohen H, Harel L, Paret G, Lahat E, Kenet G, Barzilai A. Aurioscope earpieces - a potential vector of infection? Int J Pediatr Otorhinolaryngol 1998;45:47-50.

14. Shenkman B, Linder N, Savion N, Tamarin I, Dardik R, Kenet G, German B, Varon D. Increased neonatal platelet deposition on subendothelium under flow conditions: the role of plasma von Willebrand factor. Pediatr Res 1999;45:270-275.

15. Hayek S*, Kenet G*, Lubetsky A, Rosenberg N, Gitel S, Weintroub S. Does thrombophilia play an etiological role in Legg-Calve-Perthes disease? J Bone Joint Surg Br 1999;81:686-690. *equally contributed as first authors in different disciplines

16. Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Sanford G, Inbal A. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate P™) in patients with von Willebrand disease. Thromb Haemost 81:229-233, 1999

17. Kenet G, Freedman J, Shenkman B, Brok-Simoni F, Holzman F, Brand N, Michelson A, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol 19:2017-2023, 1999

18. Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D, Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VIIa. Blood Coagul Fibrinolysis 11;Suppl S35-38, 2000

19. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 31:1283-1288, 2000

20. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M. Recombinant activated factor VII (rFVIIa) for adjunctive hemorrhage control in trauma. J Trauma 51:431-438, 2001

21. Lubetsky A, Martinowitz U, Luboshitz J, Kenet G, Keller N, Tamarin I, Dardik R, Inbal A. Efficacy and safety of a factor VIII-von Willebrand factor concentrate 8Y: stability, bacteriological safety, pharmacokinetic analysis and clinical experience. Hemophilia 8:622-628, 2002

22. Martinowitz U, Kenet G, Lubetsky A, Luboshitz J, Segal E. Possible role of recombinant


8

activated factor VII in the control of hemorrhage associated with massive trauma. Can J Anest 49:S15-S20, 2002

23. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus mega-dose of recombinant activated factor VII (NovoSeven®). J Thromb Haemost 1:450-455, 2003

24. Kenet G, Hayek S, Mor M, Lubetsky A, Miller L, Rosenberg N, Mosheiff R, Itzhaki M, Elstein D, Weintroub S, Zimran A. The 1226G (N370S) Gaucher mutation among patients with Legg-Calve-Perthes disease. Blood Cells Molec Dis 31:72-74, 2003

25. Kenet G, Maayan A, Rosenberg N, Sela BA, Mazkereth R, Yifra A, Kuint J. Thrombophilia does not increase the risk for neonatal complications in preterm infants. Thromb Haemost 90:823-828, 2003

26. Inbal A, Kenet G. Pregnancy and surgical procedures in patients with factor XIII deficiency. Biomedical Progress 16:69-71, 2003

27. Kenet G, Waldman D, Lubetsky A, Kornbrut N, Chalil A, Koren A, Wolach B, Fattal A, Kapelushnik Y, Tamary H, Yacobovitch J, Raveh E, Revel-Vilk S, Toren A, Brenner B. Pediatric cerebral sinus vein thrombosis: A multi-center, case-controlled study. Thromb Haemost 92:707-713, 2004

28. Falk B, Portal S, Tiktinsky R, Zigel L, Weinstein Y, Constantini N, Kenet G, Eliakim A, Martinowitz U. Bone properties and muscle strength of young hemophilia patients. Haemophilia 11:380-386, 2005

29. Fattal-Valevsky A, Kenet G, Kuperminc M, Mesterman R, Leitner Y, Rimon E, Harel S, Hassner A. The role of thrombophilic risk factors in children with cerebral palsy. J Thromb Res 116:133-137, 2005

30. Rosenberg N, Hauschner H., Peretz H, Mor-Cohen R, Landau M, Shenkman B, Kenet G, Coller BS, Awidi A. Seligsohn U. A 13bp deletion in �IIb gene is a founder mutation that predominates in Palestinian Arab patients with Glanzmann thrombasthenia. J Thromb Haemost 3:2764-2772, 2005

31. Schulman S, Tjønnfjord GE, Wallensten R, Martinowitz U, Kenet G. Continuous infusion of rFVIIa for surgery in patients with FVII deficiency. Thromb Haemost 94:1177-1180, 2005

32. Maor Y, Bashari D, Kenet G, Lelazari S, Lubetsky A, Luboshitz J, Schapiro JM, Avidan B, Bar Meir S, Martinowitz U. Hepatitis C at the Israeli National Hemophilia Center. Hemophilia 12:68-74, 2006

33. Levy-Shraga Y, Maayan-Metzger A, Lubetsky A, Shenkman B, Kuint J, Martinowitz U,

Kenet G. Platelet function of newborns as tested by cone and plate(let) analyzer correlates with gestational age. Acta Hematol 115:157-161, 2006

34. Maayan-Metzger A, Kuint J, Lubetsky A, Shenkman B, Mazkereth R, Kenet G. Maternal SSRI intake does not seem to affect neonatal platelet function tests. Acta Hematol 115:152-156, 2006


9

35. Kavakli K, Makris M, Zulfikar B, Erhardtsen E,Abrams ZS, Kenet G. Home treatment of haemarthroses using a single dose regimen of recombinant activated FVII in patients with haemophilia and inhibitors. Thromb Haemost. 95:600-605, 2006.

36. Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshotz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halfon P. Non invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: Can you avoid liver biopsy? Haemophilia 12:372-379, 2006

37. Berkun Y, Padeh S, Barash J, Uziel Y, Harel L, Mukamel M, Revel-Vilk S, Kenet G. Antiphospholipid syndrome in children and recurrent thrombosis. Arthritis Rheum 55:850-855, 2006

38. Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, Ottaviano F, Damasceno BP, Handy DE, Loscalzo J. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: A novel risk factor for arterial ischemic stroke among young adults and children. Stroke 38:41-49, 2007

39. Kenet G, Kirkham F, Niederstadt T, Heinecke A, Saunders D, Stoll M, Brenner B, Bidlingmaier C, Heller C, Knöfler R, Schobess R, Zieger B, Sébire G, Nowak-Göttl U and the ”European Thromboses Study Group” European collaborative paediatric database on cerebral venous thrombosis: Risk factors for recurrent venous thromboembolism. Lancet Neurol 6:595-603, 2007.

40. Zucker M, Zivelin A, Landau M, Salomon O, Kenet G, Bauduer F, Samama M, Conard J, Berruyer M, Feinstein D, Seligsohn U. Characterization of seven novel mutations causing factor XI deficiency. Haematologica 92:1375-1380, 2007.

41. Maor Y, Cales P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halfon P. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 13:722-729, 2007.

42. Herbertson M, Kenet G. Applicability and safety of recombinant activated factor VII to control non-haemophilic haemorrhage: investigational experience in 265 children. Haemophilia 14:753-762, 2008.

43. Kenet G, Ezra E, Wientroub S, Steinberg DM, Rosenberg N, Wadman D, Hayek S. Legg Calve Perthes' Disease in search of genetic associations: Collagen mutations, Gaucher disease and thrombophilia. J Bone Joint Surg Br 90:1507-1511, 2008.

44. Young G, Albisetti M, Bonduel M, Brandao L, Chan A, Friedrichs F, Goldenberg NA, Grabowski E, Heller C, Journeycake J, Kenet G, Lubetsky A, Male C, Manco-Johnson M, Mathew P, Monagle P, van Ommen H, Simioni P, Svirin P, Tormene D, Nowak-Gottl U. Impact of inherited thrombophilia on venous thromboembolism in children. A systematic review and meta-analysis of observational studies. Circulation 118:1373-1382, 2008.

45. Simchen M, Goldstein G, Lubetsky A, Strauss Z, Schiff E, Kenet G. Factor V Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 40:65-70, 2009.

46. Young G, Becker S, During C, Friedrichs F, Goldenberg N, Kenet G, Manco-Johnson M, Scheffold C, Nowak-Gottl U. Influence of the factor II G20210A variant or the factor V G1691A mutation on symptomatic recurrent venous thromboembolism (VTE) in children:


10

An international multicenter cohort study. J Thromb Haemost 7:72-79, 2009

47. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in hemophilia patients with inhibitors. Haemophilia 15:904-910, 2009.

48. Tiktinsky R, Kenet G, Dvir Z, Falk B, Heim M, Martinowitz U, Katz-Leurer M. Physical activity participation and bleeding characteristics in young patients with severe haemophilia. Haemophilia 15:695-700, 2009.

49. Kenet G, Lubetsky A, Luboshitz J, Ravid B, Tamarin I, Martinowitz U. Lower dose rFVIIa therapy is safe and effective for surgical interventions in patients with severe FXI deficiency and inhibitors. Haemophilia 15:1065-1073, 2009

50. Normann S, de Veber G, Fobker M, Langer C, Kenet G, Bernard TJ, Fiedler B, Strater R, Goldenberg NA, Nowak-Gittl U. Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol 66:754-758, 2009.

51. Kenet G, Stenmo CB, Blemings A, Wegert W, Goudemand J, Krause M, Schramm W, Kirchmaier C, Martinowitz U. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients: A multi-centre, randomized trial. Thromb Haemost 103:351-359, 2010

52. Strauss T, Levy-Shraga Y, Ravid B, Schushan-Eisen I, Maayan-Metzger A, Kuint J, Kenet G. Clot formation of neonates tested by thromboelastography correlates with gestational age. Thromb Haemost 103:344-350, 2010.

53. Strauss T, Maayan-Metzger M, Simchin J, Morag I, Shenkman B, Kenet G. Impaired platelet function in neonates born to mothers with diabetes or hypertension. Klin Padiatr 222:154-157, 2010.

54. Maayan-Metzger A, Leibovitch L, Schushan-Eisen I, Strauss T, Kenet G, Kuint J. Predictors for neonatal thrombocytopenia in infants of thrombocytopenic mothers during pregnancy. Pediatr Blood Cancer 55:145-148, 2010.

55. Revel-Vilk S, Yacobovich J, Tamary H, Goldstein G, Nemet S, Weintraub M, Paltiel M, Kenet G. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer 116:4197-4205, 2010.

56. Kenet G, Lutkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, Cowan F, de Veber G, Fiedler B, Fullerton HJ, Ganesan V, Goldenberg NA, Golomb MR, Grabowski E, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham F, Kurnik K, Lynch JK, Male C, Manco-Hohnson M, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Strater RD, Young G, Nowak-Gottl U. Impact of thrombophilia on arterial ischemic stroke or cerebral sinusvenous thrombosis in children: A systematic review and meta-analysis of observational studies. Circulation 121:1838-1847, 2010.

57. Waldman D, Manashku S, Strauss T, Goldstein G, Ben-Zeev B, Kenet G. Thrombophilia and thrombosis in children – lessons from cerebral sinus vein thrombosis registry of a tertiary center. Harefuah 149:270-273, 2010.

58. Mitchell L, Lambers M, Flege S, Kenet G, Li Thiao Te V, Holzhauer S, Bidlingmaier C, Fruhwald MC, Heller C, Schmidt W, Pautard B, Nowak-Gottl U. Validation of a predictive


11

model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia – Results of a multicenter cohort study. Blood 115:4999-5004, 2010.

59. Tirosh-Wagner T, Strauss , Rubinshtein M, Tamarin I, Mishaly D, Paret G, Kenet G. Point of Care Testing in Children Undergoing Cardiopulmonary Bypass. Pediatr Blood Cancer 56:794-798, 2011.

60. Bartfeld G, Ellis M, Lubetzky A, Yahalom V, Kenet G. Storage of blood components does not decrease haemostatic potential: In vitro assessment of fresh versus stored blood components using thromboelastography. Transfus Med Hemother. 37:329-335, 2010.

61. Strauss T, Lubetsky A, Ravid B, Bashari D, Luboshitz J, Lelazari S, Misgav M, Martinowitz U, Kenet G. Recombinant factor concentrates may increase inhibitor development: A single centre cohort study. Haemophilia. 17:625-629, 2011.

62. Simchen MJ, Oz R, Shenkman B, Zimran A, Elstein D, Kenet G. Impaired platelet function and peripartum bleeding in women with Gaucher disease. Thromb Hemost. 105:509-514, 2011.

63. Livnat T, Martinowitz U, Zivelin A, Rima D, Kenet G. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost. 105:688-695, 2011.

64. Chitlur M, Sorensen B, Rivard GE, Young G, Ingerslev J, Othman M, Nugent D, Kenet G, Escobar M, Lusher J. Standardization of thromboelastography: A report from the REG-ROTEM working group. Haemophilia. 17:532-537, 2011.

65. Morag I, Strauss T, Lubin D, Schushan-Eisen I, Kenet G, Kuint J. Restrictive management of neonatal polycythemia. Am J Perinatol. 28:677-682, 2011.

66. Livnat T, Shenkman B, Kenet G, Tamarin I, Gillis S, Varon D, Iijima K, Zivelin A, Salomon O. Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry. Blood Coagul Fibrinolysis. 22:673-679, 2011.

67. Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: A systematic review and meta-analysis. Semin Thromb Hemost. 37:802-809, 2011.

68. Bidlingmaier C, Kenet G, Kurnik K, Mathew P, Manner D, Mitchell L, Krumpel A, Nowak-Göttl U. Safety and efficacy of low molecular weight heparins in children: A systematic review of the literature and meta-analysis of single-arm studies. Semin Thromb Hemost. 37:814-825, 2011.

69. Sorensen B, Dargaud Y, Kenet G, Lusher J, Mumford A, Pipe S, Tiede A. On-demand treatment of bleeds in haemophilia patients with inhibitors: Strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia. 18:255-262, 2012.


12

70. Givol N, Goldstein G, Peleg O, Shenkman B, Zimran A, Elstein D, Kenet G. Thrombocytopenia and bleeding in dental procedures of patients with Gaucher disease. Haemophilia. 18:117-121, 2012.

71. Ben Simon GJ, Kenet G, Spierer A. Fibrinoid reaction after lens extraction in rabbit eyes. J Cataract Refract Surg. 38:890-893, 2012.

72. Forsythe AL, Giangrande P, Hay CR, Kenet G, Kessler CM, Knobl PN, Llinas A, Santagostino E, Young G. Difficult clinical challenges in haemophilia: International experiential perspectives. Haemophilia. 5:39-45, 2012.

73. Maayan-Metzger A, Lubetsky A, Kuint J, Rosenberg N, Simchen MJ, Kuperman A, Strauss T, Sela BA, Kenet G. The impact of genetic and environmental factors on homocysteine levels in preterm neonates. Pediatr Blood Cancer. 60:659-662, 2012.

74. Lambers M, Goldenberg NA, Kenet G, Kirkham FJ, Manner D, Bernard T, Mesters RM, Junker R, Stoll M, Nowak-Göttl U. Role of reduced ADAMTS13 in arterial ischemic stroke: A Pediatric Cohort Study. Ann Neurol. 73:58-64, 2013.

75. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Factor VIII Products and inhibitor development in Severe Hemophilia A. N Engl J Med. 368:231-239, 2013.

76. Misgav M, Kenet G, Martinowitz U. Chitosan-based dressing for the treatment of external/accessible bleedings in children with bleeding tendency. J Pediatr Hematol Oncol. 36:140-142, 2014.

77. Livnat T, Martinowitz U, Azar-Avivi S, Zivelin A, Brutman-Barazani T, Lubetsky A, Kenet G. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors - a thrombin generation-guided pilot study. Haemophilia. 19:782-789, 2013.

78. Halimeh S, Bidlingmaier C, Heller C, Gutsche S, Holzhauer S, Kenet G, Kurnik K, Manner D, Iorio A, Nowak-Göttl U. Risk factors for high-titer inhibitor development in children with hemophilia a: results of a cohort study. BioMed Res Int. 2013:901975, 2013.

79. Strauss T, Rozenzweig N, Rosenberg N, Shenkman B, Livnat T, Morag I, Fruchtman Y, Martinowitz U, Kenet G. Surfactant impairs coagulation in-vitro: a risk factor for pulmonary hemorrhage? Thromb Res. 132:599-603, 2013.

80. Kenet G, Bidlingmaier C, Bogdanova N, Escuriola Ettingshausen C, Goldenberg N, Gutsche S, Halimeh S, Holzhauer S, Kurnik K, Limperger V, Junker R, Nowak-Göttl U. Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A - an Israeli-German multicenter database study. Thromb Res. 133:544-549, 2014.

81. Berkun Y, Simchen MJ, Strauss T, Menascu S, Padeh S, Kenet G. Antiphospholipid antibodies in neonates with stroke - a unique entity or variant of antiphospholipid syndrome? Lupus. 23:986-993, 2014.


13

82. Limperger V, Franke A, Kenet G, Holzhauer S, Picard V, Junker R, Heller C, Gille C, Manner D, Kurnik K, Knoefler R, Mesters R, Halimeh S, Nowak-Göttl U. Clinical and laboratory characteristics of pediatric and adolescent index cases with venous thromboembolism and antithrombin deficiency: An observational multicenter cohort study. Thromb Haemost. 112:478-485, 2014.

83. Limperger V, Klostermeier UC, Kenet G, Holzhauer S, Alhenc Gelas M, Finckh U, Junker R, Heller C, Zieger B, Kurnik K, Knöfler R, Mesters R, Halimeh S, Nowak-Göttl U. Clinical and laboratory characteristics of children with venous thromboembolism and protein C-deficiency: an observational Israeli-German cohort study. Br J Haematol. 167:385-393, 2014.

84. Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost . 113:958-967, 2015.

85. Givol N, Hirschhorn A, Lubetsky A, Bashari D, Kenet G. Oral surgery-associated postoperative bleeding in haemophilia patients - a tertiary centre's two decade experience. Haemophilia. 21:234-240, 2015.

86. Yacobovich J, Ben-Ami T, Abdalla T, Tamary H, Goldstein G, Weintraub M, Yaniv I, Toren A, Kenet G, Revel-Vilk S. Patient and central venous catheter related risk factors for blood stream infections in children receiving chemotherapy. Pediatr Blood Cancer. 62:471-476, 2015.

87. Klostermeier UC, Limperger V, Kenet G, Kurnik K, Alhenc Gelas M, Finckh U, Junker R, Heller C, Zieger B, Knöfler R, Holzhauer S, Mesters R, Krümpel A, Nowak-Göttl U. Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study. Thromb Haemost. 113:426-433, 2015.

88. Ioscovich A, Fadeev D, Kenet G, Naamad M, Schtrechman G, Zimran A, Elstein D. Thromboelastography as a Surrogate Marker of Perisurgical Hemostasis in Gaucher Disease Clin Appl Thromb Hemost. 22:693-697, 2016.

89. Rodriguez V, Mancuso ME, Warad D, Hay CR, DiMichele DM, Valentino L, Kenet G, Kulkarni R. Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study. Haemophilia. 21:e369-74, 2015.

90. Fruchtman Y, Strauss T, Rubinstein M, Ben Harush M, Revel-Vilk S, Kapelushmik J, Paret G, Kenet G. Skin Necrosis and Purpura Fulminans in Children With and Without Thrombophilia--A Tertiary Center's Experience Pediatr Hematol Oncol. 32:505-10, 2015.

91. van den Berg HM, Hashemi SM, Fischer K, Petrini P, Ljung R, Rafowicz A, Carcao M, Auerswald G, Kurnik K, Kenet G, Santagostino E; PedNet Study group. Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors Thromb Haemost. 115:729-737, 2016.

92. Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M; investigators of the LEOPOLD Kids Trial. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated


14

children with severe haemophilia A: results of the LEOPOLD Kids Trial Haemophilia.22:354-360, 2016.

93. Sidlik R, Strauss T, Morag I, Shenkman B, Tamarin I, Lubetsky A, Livnat T, Kenet G. Assessment of Functional Fibrinolysis in Cord Blood Using Modified Thromboelastography. Pediatr Blood Cancer. 63:839-43, 2016.

94. Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott

DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C. Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. Haemophilia. 22 Suppl 1:1-24, 2016.

95. Astermark J, Hart D, Lobet S, Blatný J, d'Oiron R, Kenet G, Dolan G, Libotte V, Hermans C. Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015. Eur J Haematol. 97 Suppl 84:3-23, 2016.

96. Krause M, Henningsen A, Torge A, Juhl D, Junker R, Kenet G, Kowalski D, Limperger V, Mesters R, Anonymous, Rocke A, Shneyder M, Clausnizer H, Schiesewitz H, Nowak-Göttl U. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. Thromb Res. 148:145-151, 2016.

97. Napolitano M, Di Minno MN, Batorova A, Dolce A, Giansily-Blaizot M, Ingerslev J, Schved JF, Auerswald G, Kenet G, Karimi M, Shamsi T, Ruiz de Sáez A, Dolatkhah R, Chuansumrit A, Bertrand MA, Mariani G. Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. Haemophilia. 22:752-759, 2016.

98.

Limperger V, Kenet G, Goldenberg NA, Heller C, Holzhauer S, Junker R, Klostermeier UC, Knoefler R, Kurnik K, Krümpel A, Mesters R, Stach M, Young G, Nowak-Göttl U. Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. Br J Haematol. 175:133-40, 2016.

99. Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, Mancuso ME, Curtin J, Voigt C, Li Y, Jacobs I, Santagostino E; PROLONG-9FP Investigator Study Group Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. Thromb Haemost. 116:659-68, 2016.

100. Brüwer G, Limperger V, Kenet G, Klostermeier UC, Shneyder M, Degenhardt F, Finckh

U, Heller C, Holzhauer S, Trappe R, Kentouche K, Knoefler R, Kurnik K, Krümpel A, Lauten M, Manner D, Mesters R, Junker R, Nowak-Göttl U. Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study. Blood Cells Mol Dis. 62:24-31, 2016.

101. Misgav M, Mandelbaum T, Kassif Y, Berkenstadt H, Tamarin I, Kenet G. Thromboelastography during coronary artery bypass grafting surgery of severe hemophilia A patient - the effect of heparin and protamine on factor VIII activity. Blood Coagul Fibrinolysis. 28:329-333, 2017.

102. Revel-Vilk S, Richter C, Ben-Ami T, Yacobovich J, Aviner S, Ben-Barak A, Kuperman AA,


15

Ben-Barak S, Kaplinsky C, Miskin H, Tamary H, Kenet G. Quantitation of bleeding symptoms in a national registry of patients with inherited platelet disorders. Blood Cells Mol Dis. 67:59-62, 2017.

103. Kenet G, Limperger V, Shneyder M, Nowak-Göttl U. Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents - What did we learn within the last 20 years? Blood Cells Mol Dis. 67:18-22, 2017.

104. Misgav M, Mandelbaum T, Kassif Y, Berkenstadt H, Tamarin I, Kenet G.

Thromboelastography during coronary artery bypass grafting surgery of severe hemophilia A patient – the effect of heparin and protamine on factor VIII activity. Blood Coagul Fibrinol. 28:329-333, 2017.

105. Kuperman AA, Barg AA, Fruchtman Y, Shaoul E, Rosenberg N, Kenet G, Livnat T.

Primary prophylaxis for children with severe congenital factor VII deficiency - Clinical and laboratory assessment. Blood Cells Mol Dis. 67:86-90, 2017.

106. Strauss T, Elisha N, Ravid B, Rosenberg N, Lubetsky A, Levy-Mendelovich S, Morag I,

Nowak Göttl U, Kenet G. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates. Blood Cells Mol Dis. 67:14-17, 2017.

107. Nowak-Göttl U, Limperger V, Kenet G, Degenhardt F, Arlt R, Domschikowski J,

Clausnizer H, Liebsch J, Junker R, Steppat D. Developmental hemostasis: A lifespan from neonates and pregnancy to the young and elderly adult in a European white population. Blood Cells Mol Dis. 67:2-13, 2017.

108. Leiba M, Malkiel S, Budnik I, Rozic G, Avigdor A, Duek A, Nagler A, Kenet G, Livnat T.

Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. Blood Cells Mol Dis. 65:1-7, 2017.

109. Kenet G, Oladapo A, Epstein JD, Thompson C, Novack A, Nugent DJ. Estimating the

potential cost of a high dose immune tolerance induction (ITI) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis. Haemophilia. 23:e394-e402, 2017.

110. Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, Hoffmann

M, Kavakli K, Kenet G, Kobelt R, Kurnik K, Liesner R, Mäkipernaa A, Manco-Johnson MJ, Mancuso ME, Molinari AC, Nolan B, Perez Garrido R, Petrini P, Platokouki HE, Shapiro AD, Wu R, Ljung R. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol. 179:298-307, 2017.

111. Livnat T, Budnik I, Levy-Mendelovich S, Avishai E, Misgav M, Barg AA, Lubetsky A,

Brutman-Barazani T, Kenet G. Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. Blood Cells Mol Dis. 66:1-5, 2017.

112. Ehrlich R, Zahavi A, Axer-Siegel R, Budnik I, Dreznik A, Dahbash M, Nisgav Y, Megiddo

E, Kenet G, Weinberger D, Livnat T. Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal Diseases. Curr Eye Res. June 20, 2017. In press.

113. Levy-Mendelovich S, Lev A, Aviner S, Rosenberg N, Kaplinsky C, Sharon N, Miskin H,


16

Dvir A, Kenet G, Schushan IE, Somech R. Quantification of specific T and B cells immunological markers in children with chronic and transient ITP. Pediatr Blood Cancer. Dec;64(12), 2017.

114. Misgav M, Lubetszki A, Brutman-Barazani T, Martinowitz U, Kenet G. The hemostatic

efficacy of chitosan-pads in hemodialysis patients with significant bleeding tendency. J Vasc Access. 15;18(3):220-224, 2017.

115. Groot N, de Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, Kenet G,

Koné-Paut I, Lahdenne P, Marks SD, McCann L, Pilkington CA, Ravelli A, van Royen-Kerkhof A, Uziel Y, Vastert SJ, Wulffraat NM, Ozen S, Brogan P, Kamphuis S, Beresford MW. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Ann Rheum Dis. 76:1637-1641, 2017.

116. Barg AA, Livnat T, Kenet G. An extra X does not prevent acquired hemophilia -

Pregnancy-associated acquired hemophilia A. Thromb Res. 151 Suppl 1:S82-S85, 2017.

117. Barg AA, Ifrah AD, Strauss T, Simchen MJ, Orvieto R, Rosenberg N, Kenet G. A man-made disease: Fetal neonatal alloimmune thrombocytopenia due to incompatibility between oocyte donor and gestational mother. Pediatr Blood Cancer. 64(8), 2017.

118. Pollak U, Mishaly D, Kenet G, Vardi A. Heparin-induced thrombocytopenia complicating

children after the Fontan procedure: Single-center experience and review of the literature. Congenit Heart Dis. 13(1):16-25, 2018.

119. Barg AA, Livnat T, Kenet G. Inhibitors in Hemophilia: Treatment challenges and novel

options. Semin Thromb Hemost. 12 Dec. 2017. In press.

120. Mancuso ME, Fischer K, Santagostino E, Oldenburg J, Platokouki H, Königs C, Escuriola-Ettingshausen C, Rivard GE, Cid AR, Carcao M, Ljung R, Petrini P, Altisent C, Kenet G, Liesner R, Kurnik K, Auerswald G, Chambost H, Mäkipernaa A, Molinari AC, Williams M, van den Berg HM, European Pediatric Network for Haemophilia Management (PedNet) the REMAIN (REal life MAnagement of children with INhibitors) Study Group. Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. Thromb Haemost. 117:2274-2282, 2017.

121. Barg AA, Levy Mendelovich S, Lalezari S, Azar Avivi S, Bashari D, Kenet G. Neonatal

circumcision in patients with haemophilia is safe – a single centre experience. J Haem Pract. 4(1), 2017.

122. Barliya T, Dardik R, Nisgav Y, Dachbash M, Gaton D, Kenet G, Ehrlich R, Weinberger D,

Livnat T. Possible involvement of NETosis in inflammatory processes in the eye: Evidence from a small cohort of patients. Mol Vis. 23:922-932. eCollection 2017.

123. Platokouki H, Fischer K, Gouw SC, Rafowicz A, Carcao M, Kenet G, Liesner R, Kurnik K,

Rivard GE, van den Berg HM. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia. 15 Dec. 2017. In press.

124. Levy-Mendelovich S, Barg AA, Rosenberg N, Avishai E, Luboshitz J, Misgav M, Kenet G,

Livnat T. Treatment tailoring for factor V deficient patients and perioperative management using global hemostatic coagulation assays. Blood Cells Mol Dis. 2018


17

Feb 2. S1079-9796(17)30507-7. In press.

125. Bar-Ilan A, Livnat T, Hoffmann M, Binder L, Zakar M, Guy R, Felikman Y, Moschcovich L, Shenkman B, Monroe D, Hershkovitz O, Kenet G, Hart G. In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII. Haemophilia. 2018 (Mar. 14). In press.

CASE REPORTS

1. Toren A, Kende G, Mandel M, Biniaminov M, Brok-Simoni F, Rosenthal E, Engelberg I, Neumann Y, Kenet G, Ben-Bassat I, et-al. In vivo clonal evolution of pre-B to B-cell acute lymphoblastic leukemia in childhood. Leukemia 8:1062-1064, 1994.

2. Kende G, Toren A, Mandel M, Neumann Y, Kenet G, Ben-Bassat I, Rechavi G. Familial leukemia: description of two kindreds and a review of the genetic aspects of the disease. Acta Hematol 92:208-211, 1994.

3. Berkowicz M, Toren A, Rosner E, Mandel M, Vonsover A, Biniaminov M, Amariglio N, Mark Z, Kenet G, Neumann Y, et-al. Lymphomatous T-cell leukemia in two Arab children. Is there a role for an environmental effect? Leukemia 8:1995-1998, 1994.

4. Kenet G, Mandel M, Mor Y, Toren A, Jonas P, Neumann Y, Kende G, Rechavi G. Genetic predisposition and cyclophosphamide treatment in a girl with bladder carcinoma. Med Ped Oncol 24:269-270, 1995.

5. Neumann Y, Toren A, Rechavi G, Seigried B,Shoham NG, Mandel M, Kenet G, Sharon N, Sadeh M, Navon R. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Med Pediatr Oncol 26:280-283, 1996.

6. Toren A, Neumann Y, Rosner E, Schiby G, Paret G, Biniaminov M, Amariglio N, Mark Z, Mandel M, Kenet G, Bercowicz M, Rubnov V, Rosenthal E, Brok-simoni F, Rechavi G. Pediatric small cell variant of Ki-1 (CD30) + T-cell lymphoma with germ-line configuration of the T-cell receptor gene. Acta Oncol 35:243-245, 1996.

7. Toren A, Mandel M, Passwell J, Biniaminov M, Neumann Y, Rosenthal E, Kende G, Kenet G, Brok-Simoni F, Rechavi G. Lack of N-myc-amplification and normal karyotype in stage IV-N neuroblastoma. Acta Oncol 35:496-498, 1996.

8. Kaplinsky C, Toren A, Neumann Y, Mandel M, Kenet G, Sharon N, Rechavi G, Biniaminov M, Rubanov V, Rosenthal E, Rosner E, Mark Z, Amariglio N, Brok-Simoni F. Central nervous system involvement at diagnosis in a case of pediatric CD30+ anaplastic large cell lymphoma. Med Pediatr Oncol 28:132-135, 1997.

9. Sharon N, Kenet G, Toren A, Mandel M, Neumann Y, Kaplinsky C, Schiby G, Rechavi G. Helicobacter pylori-associated gastric lymphoma in a girl. Pediatr Hematol Oncol 14:177-180, 1997.

10 Kenet G, Sharon N, Rosner E, Toren A, Neumann Y, Mandel M, Kaplinsky C, Gipsh N, Berman S, Rechavi G. Chromosomal translocation (1:13) in a case of alveolar rhabdomyosarcoma. J Ped Hematol Oncol 20:86-87, 1998.


18

11 Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with

recombinant factor VIIa. Lancet 354:1879, 1999.

12 Sharon N, Neumann Y, Kenet G, Schachter J, Rechavi G, Toren A. Successful pregnancy after high-dose Cyclophosphamide and Ifosfamide treatment in two postpubertal women. Ped Hematol Oncol 18:247-252, 2001.

13 Leibovitch L, Kenet G, Mazor K, Matok I, Vardi A, Barzilay Z, Paret G. Recombinant activated factor VII for life threatening pulmonary hemorrhage following pediatric cardiac surgery. Ped Crit Care Med 4:444-446, 2003.

14 Rosenzweig N, Strauss T, Rubinstein M, Paret G, Kenet G. Activated protein C concentrate treatment for skin necrosis under warfarin treatment in severe genetic protein C deficiency combined with prothrombin mutation and factor V Leiden. Thromb Haemost 101:405-407, 2009.

15 Strauss T, Kenet G, Schushan-Eisen I, Mazkereth R, Kuint J. Rescue recombinant activated factor VII for neonatal subgaleal hemorrhage. Isr Med Assoc J 11:638-640, 2009.

16 Fruchtman Y, Dardik R, Barg AA, Livnat T, Feldman Z, Rubinstein M, Grinberg G, Rosenberg N, Kenet G. Spinal Epidural Hematoma Following Cupping Glass Treatment in an Infant With Hemophilia A. Pediatr Blood Cancer. 63:1120-2, 2016.

REVIEW ARTICLES

1. Balin A., Kenet G. Autologous cord blood transfusion. Harefuah 124:554-556, 1993

באלין ע., קנת ג: עירוי עצמי של דם השורר. הרפואה 1993, 124, 554-556 .2

3. Goldstein G, Kenet G. The impact of chronic disease on the family. Haemophilia 8, 461- 465; 2002

4. Kenet G. The use of rFVIIa (NovoSeven®) for hemorrhage control in trauma patients. Trans Alt Trans Med 5:48-51, 2003

5. Abshire T, Kenet G. Recombinant activated factor VII: Review of efficacy, dosing regimens and safety in patients with hemophilia and FVIII or FIX inhibitors, or acquired hemophilia. J Thromb Haemost 2:899-909, 2004

6. Brenner B, Grabowski EF, Hellgren M, Kenet G, Massicote P, Manco-Johnson M, Mathew P, Muntean W, Schleggel N, Nowak-Gottl G. Thrombophilia and pregnancy complications. Thromb Haemost 92:678-681, 2004

7. Kenet G. Bleeding disorders in neonates. Thromb Res 115 Suppl 1:41-44, 2005

8. Ravel-Vilk S, Kenet G. Thrombophilia in children with venous thromboembolic disease. Thromb Res 118:59-65, 2006

9. Kenet G, Nowak-Gottl U. Bleeding and thrombosis issues in pediatric patients: Current approach to diagnosis and treatment. Acta Haematol 115:137-40, 2006


19

10. Kenet G. High dose recombinant factor VIIa therapy in hemophilia patients with

inhibitors. Seminar Hematol 43:S108-S110, 2006

11. Kenet G, Nowak-Gottl U. Fetal and neonatal thrombophilia. Obstet Gynecol Clin North Am 33:457-466, 2006

12. Nowak-Gottl U, Bidlingmaier C, Krumpel A, Gottl L, Kenet G. Pharmacokinetids, efficacy, and safety of LMWHs in venous thrombosis and stroker in neonates, infants and children. Br J Pharmacol 153:1120-1127, 2007

13. Berkun Y, Kenet G. Pediatric antiphospholipid syndrome. Isr Med Assoc 10:45-47, 2008

14. Kenet G, Martinowitz U. Single dose rFVIIa therapy in hemophilia patients with inhibitors. Semin Hematol 45:S38-S41, 2008

15. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 14:898-902, 2008

16. Kenet G, Strauss T, Kaplinsky C, Paret G. Hemostasis and thrombosis in critically ill Children. Semin Thromb Hemost 34:451-458, 2008

17. Kenet G, Krumpel A, Nowak-Gottl U. Bleeding issues in neonates, infants and young children. Thromb Res 123:S35-S37, 2009

18. Nowak-Gottl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: Epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 22:103-114, 2009

19. Schlegel N, Bardet V, Kenet G, Muntean W, Zieger, B, Nowak-Gottl U. Diagnostic and therapeutic considerations on inherited platelet disorders in neonates and children. Klin Padiatr 222:209-214, 2010

20. Iorio A, Halimeh A, Hozhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knofler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Gottl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor III concentrates: A systematic review. J Thromb Haemost 8:1256-1265, 2010

21. Goldenberg NA, Donadini MP, Kahn SR, Crowther M, Kenet G, Nowak-Gottle U, Manco-Johnson MJ. Post thrombotic syndrome in children: a systematic review of frequency of occurrence, validity of outcome measures, and prognostic factors. Haematologica 95:1952-1959, 2010

22. Kenet G, Gottle UN. Thrombosis in children and neonates. Thromb Res 126:463-464, 2010

23. Kenet G, Chan AK, Soucle JM, Kulkarni R. Bleeding disorders in neonates. Haemophiila 5:168-175, 2010


20

24. Kenet G, Kuperman AA, Strauss T, Brenner B. Neonatal IVH – Mechanisms and management. Thromb Res 2011;12753:S120-S122.

25. Menascu S, Lotan A, Ben Zeev B, Nowak-Göttl U, Kenet G. Cerebral venous thrombosis in the Mediterranean area in children. Mediterr J Hematol Infect Dis 2011;3:e2011029.

26. Strauss T, Sidlik-Muskatel R, Kenet G. Developmental hemostasis: Primary hemostasis and evaluation of platelet function in neonates. Semin Fetal Neonatal Med 2011;16:301-304.

27. Nowak-Göttl U, Kurnik K, Manner D, Kenet G. Thrombophilia testing in neonates and infants with thrombosis. Semin Fetal Neonatal Med 2011;16:345-348.

28. Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Göttl U. Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost 2011;9:1856-1858

29. Kenet G, Nowak-Göttl U. Thrombotic and bleeding disorders in perinatal medicine. Semin Fetal Neonatal Med 2011;16:293.

30. Kenet G, Nowak-Göttl U. Hemostasis and thrombosis in pediatric patients: Special issues and unique concerns. Semin Thromb Hemost 2011;37:721-722.

31. Kuperman AA, Kenet G, Papadakis E, Brenner B. Intraventricular hemorrhage in preterm infants: Coagulation perspectives. Semin Thromb Hemost 2011;37:730-736.

32. Kenet G, Nowak-Göttl U. Venous thromboembolism in neonates and children. Best Practice Res Clin Haematol 2012;25:333-344.

33. Kuperman A.A, Brenner B, Kenet G. Intraventricular hemorrhage in preterm infant and coagulation - ambivalent perspectives? Thromb Res 2013;131:S35-38.

34. Nowak-Göttl U, Janssen V, Manner D, Kenet G. Venous thromboembolism in neonates and children--update 2013. Thromb Res 2013;131:S39-41.

35. Kuperman AA, Brenner B, Kenet G. Intraventricular haemorrhage in preterm infants - Can we improve outcome by addressing coagulation? J Matern Fetal Neonatal Med 2013, August 23.

36. Nowak-Göttl U, Kenet G. Challenging aspects of managing hemostasis in adolescents. Acta Haematol 2014;132:326-330.

37. Nowak-Göttl U, Limperger V, Bauer A, Kowalski D, Kenet G. Bleeding issues in neonates and infants - update 2015. Thromb Res. 2015 Feb;135 Suppl 1:S41-3.

38. Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C. Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in


21

Paris, France on 20 November 2014 (Review). Haemophilia. 2016 Jan;22 Suppl 1:1-24.

39. Livnat T, Barg AA, Levy-Mendelovich S, Kenet G. Rare bleeding disorders-old

diseases in the era of novel options for therapy. Blood Cells Mol Dis. 67:63-68, 2017.

40. Levy-Mendelovich S, Barg AA, Kenet G. Thrombosis in pediatric patients with

leukemia. Thrombosis Research, 2018. In press.

41. Nowak-Göttl U, van Ommen H, Kenet G. Thrombophilia testing in children: What and when should be tested? Thromb Res. 164:75-78, 2018.


22

CHAPTERS IN BOOKS 1. Kenet G, Rechavi G. Chapters: Blood diseases: 717-765; In: Pediatrics, Ashkenazi S,

Shohat M. (Hebrew). Dionon University of Tel-Aviv press. Vol. 4 p. 717-765, 1994. Updated Vol. 5, 1998.

2. Kenet G, Rechavi G. Neoplastic diseases: 765-808. In: Pediatrics, Ashkenazi S, Shohat M.

(Hebrew). Dionon University of Tel-Aviv press. Vol. 4 p. 717-765, 1994. Updated Vol. 5, 1998.

3. Kaplinsky C, Kenet G, Rechavi G. Coagulation, bone marrow and blood cells, immune

system. Principals and practic of Pediatric Anesthesia. Editors: Bernard Dalens and Bruno Bissonnette, McGraw Hill, New York USA, 2000.

4. Kenet G. Bleeding disorders in neonates. Women’s issues in Hemostasis. Editors: Brenner

B, Marder VJ, Conrad J. Martin Dunitz Publishers, London, UK, 2002. 5. Kenet G, Martinowitz U. Standard high and mega bolus doses of rFVIIa: Comparison of

three treatment regimens. Inhibitors in patients with Haemophilia. Editors: EC Rodriguez-Merchan, CA Lee. Blackwell-Science, USA, 2002.

6. Kaplinsky C, Somech R, Kenet G. Principles of hematopoiesis, immunity and coagulation.

Editors: Bernard Dalens and Bruno Bissonnette, McGraw Hill, New York USA, 2010. 7. Kenet G, Nowak-Gottl U. Venous thromboembolism in neonates and children. In: Best

Practice Res Clin Haematol 25:333-344, Editors: Brenner B, Row J. Elsevier Ltd, 2012. 8. Nowak-Göttl U, Kenet G, Goldenberg NA. Pediatric thrombophilia evaluation: considerations

for primary and secondary venous thromboembolism prevention, ch. 10. In: Pediatric Thrombotic Disorders, ed. Neil A. Goldenberg and Marilyn J. Manco-Johnson. Cambridge University Press 2015, pp. 133-141.

9. Moharir M, Kenet G. Cerebral sinovenous thrombosis in children and neonates, ch. 2. In:

Pediatric Thrombotic Disorders, ed. Neil A. Goldenberg and Marilyn J. Manco-Johnson. Cambridge University Press 2015.


23

INVITED PAPERS IN SCIENTIFIC MEETINGS 1. Kenet G, Martinowitz U. Continuous infusion of recombinant VIIa. The 5th Novo Nordisk

Symposium on the treatment of bleeding and thrombotic disorders, Copenhagen, Denmark, 1999.

2. Kenet G. Use of rFVIIa in patients without preexisting coagulation disorders. GTH, 2001. 3. Kenet G. Standard, high and mega bolus doses of novoseven-comparison of different

treatment regimens-a single center experience. The Novonordisk symposium, Copenhagen, 2001.

4. Kenet G. The use of novoseven for profuse bleeding in surgical patients. The Novonordisk

symposium, Copenhagen, 2001. 5. Kenet G. Treatment of young hemophilia patients with inhibitors by recombinant activated

factor VIIa. Annual Pediatric Hematology Congress, Ankara, 2001. 6. Kenet G. Management of catastrophic bleeding episodes. ASH, Orlando, 2001. 7. Kenet G, Martinowitz U. Circumcision in neonates with Hemophilia. WFH, Seville, 2002. 8. Kenet G, Lubetsky A, Inbal A et al: Pediatric stroke in Israel. SSC of ISTH, Boston, 2002. 9. Kenet G. Catastrophic trauma and massive hemorrhage in: Excessive bleeding in bone-

marrow transplantation, ASBMT, Keystone, USA, 2003. 10. Kenet G. Pediatric thrombophilia-have we figured it all out? Israeli Society of Clinical

Pediatrics, Tel-Aviv, 2003. 11. Kenet G. Pediatric Cerebral sinus vein thrombosis and thrombophilia – ISTH Birmingham

2003. 12. Kenet G. Use of rFVIIa in trauma- the Israeli experience. TSIS, Munich, Germany, March

2004. 13. Kenet G. Recombinant activated FVIIa for lifesaving treatment in hemorrhage. SMART,

Milano, May 2004. 14. Kenet G. High dose RFVIIa for treatment of hemophilia patients with inhibitors. The Fourth

Hemostasis symposium, Fukuoka, Japan, April 2004. 15. Kenet G. Coagulation tests as predictors of bleeding in children on cardiopulmonary bypass.

Pediatric Perinatal SSC, Venice Italy, June 2004. 16. Kenet G. Optimizing the use of rFVIIa in Hemophilia WFH, Bangkok, Thailand October 2004. 17. Kenet G. The bleeding neonate. International Symposium on Women's Health Issues in

Thrombosis and Hemostasis Budapest, Hungary, February 4-6, 2005. 18. Kenet G. A critical perspective on recombinant factor VIIa. EHA Congress June 2-5, 2005

Stockholm, Sweden.


24

19. Kenet G. Comparison of standard vs higher dosing of rFVIIa for the treatment of bleeds in inhibitor patients ISTH Sydney, 2005.

20. Kenet G, Schlegel N. Coagulation tests as predictors of Bleeding in children undergoing

tonsillectomy and adenoidectomy. New ways to predict bleeding /When should we test Pediatric/perinatal SSC ISTH Sydney, August 2005

21. Kenet G. Life quality of hemophilia patients-more than hemostasis WFH Vancouver Canada,

May 2006 22. Kenet G. Antiphospholipid Antibodies: Risk of thrombosis in children with APLA; Results of

the Israeli experience SSC ISTH, Oslo Norway, June 2006. 23. Kenet G. Perinatal-neonatal arterial stroke (PNAS) and acquired thrombophilia. PNAS special

conference NIH, Bethesda August 2006. 24. Kenet G. Developmental hemostasis and bleeding in the neonate. WHITH, Vienna, Austria,

February 2007. 25. Kenet G. 1. Pediatric thrombophilia and thrombosis. 2. Pediatric antiphospholipid syndrome.

Congress Latin America Hemostasis and Thrombosis (CLAHT), Buenos Aires, April 2008. 26. Kenet G. Treatment of pediatric thromboembolism. Mediterranean League against

thromboembolic disease (MLTD), Athens, Greece, June 2008. 27. Kenet G. Future perspectives of inhibitor treatment. WFH, Istanbul, Turkey, June 1-5, 2008. 28. Kenet G. Diagnosis and Treatment of Bleeding Disorders in Preterm and Term Neonates

(state-of-the art) GTH, Vienna, Austria, Feb. 3-7, 2009. 29. Kenet G. Developmental Hemostasis-Educational Session of SSC, ISTH, Boston, USA, 2009. 30. Kenet G. Other bleeding disorders in neonates - state of the art, WFH, Buenos Aires,

Argentina, July 2010. 31. Kenet G. Challenges in treatment and monitoring of hemophilia- lessons learned from inhibitor

patients. State of the art, ISH, Jerusalem, October 2010. 32. Kenet G. Little people with large clots- ISH, Jerusalem, October 2010. 33. Kenet G. New anticoagulants in children. SHIP, Marseilles, France, October 2010. 34. Kenet G. IVH in neonates- pathogenesis and mechanisms. WHITH, Berlin, Germany,

February 2011. 35. Kenet G. Thrombosis and Hemostasis in women and children. PNAS, Padua, Italy, May 2011. 36. Kenet G. Tailored therapy for hemophilia patients with inhibitors: thrombin generation guided

protocols. Emory University, Atlanta, USA, 2012 37. Kenet G. IVH in neonates. WHITH, Vienna, Austria, 2013


25

38. Kenet G. The role of thrombin generation in hemophilia patients. Inhibnitor symposium of Nijmegen University, Nijmegen, Netherlands, 2013

39. Kenet G. Thrombosis and hemostasis in neonates. EHA, Stockholm, Sweden, 2013 40. Kenet G. FVIII levels should not be kept above 5% during prophylaxis. ISTH, Amsterdam, NL,

July 2013 41. Kenet G, Strauss T. Developmental hemostasis - bleeding vs thrombosis. ESPHI, Kiel,

Germany, Oct 2013 42. Kenet G. Future perspectives of hemophilia care: Turoctocogalfa - A 3rd generation FVIII

replacement therapy and other options for improved quality of life of patients with hemophilia. Hematocon, Mumbai, India, Nov 2013

43. Kenet G. Bleeding disorders other than hemophilia- meet the professor seesion. Hematocon,

Mumbai, India, Nov 2013 44. Kenet G. IVH- a bleeding disorder or prothrombotic etiology? Copedia, Prague, Check

Republic, April 2014 45. Kenet G. Developmental aspects of hemostasis. Copedia, Prague, Check republic, April 2014 46. Kenet G Thrombosis of the brain- anticoagulant therapy in children with arterial ischemic

stroke or cerebral sinus vein thrombosis. MLTD, Valencia, Spain, May 2014 47. Kenet G. Hemostasis and Thrombosis of neonates. SSC of ISTH, Milwaukee, USA, June

2014 48. Kenet G. Use of bypass agents- rFVIIa vs Feiba and use of thrombin generation for treatment

tailoring in patients with hemophilia and inhibitors. CITH, Berlin, Germany, October 2014 49. Kenet G. Debate: ITI treatment and tailoring in patients with inhibitors. Octaday, Paris, France.

November 2014 50. Kenet G. Advancing with purpose: The LEOPOLD Study Programme. EHAD, Helsinki,

Finland, February 2015 ITEMS IN ENCYCLOPEDIAS

דממת (המופיליה) -ואוריאל מרטינוביץ גילי קנת. (Hemophilia) האנציקלופדיה הישראלית לרפואה בדפוס.-הוצאת ידיעות אחרונות-בעריכת פרופ יהודה שיינפלד

OTHER PUBLICATIONS

1. Maimon M, Bernstein T, Kenet G, Kapelushnik J. Recombinant factor VIIa for treatment of a child with severe factor VII deficiency and coarctation of the aorta. J Ped Hematol Oncol 2003;25:591 – letter.

2. Poon MC, D’Orion R, Von Depka M et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. JTH 2004 - I was a member of the international data collection


26

on rFVIIa and congenital platelet disorders study group (see acknoledgements).

3. Martinowitz U, Michaelson M and the Israeli Multidisciplinary rFVIIa task force. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 2005 Apr;3(4):640-8 (I was among members of task force).

4. Avcin T, Climaz R, Rozman B, Ped-APS Registry Collaborative Group. The Ped-APS Registry: The antiphospholipid syndrome in childhood. Lupus 18:894-899, 2009.

גילי קנת,דר' - זיהוי וריפוי גנטי של מחלת ההמופיליה-מחלה עם תקוה .5 Medicine Hematology, 4 Apr. 2009.

2009דר' גילי קנת, עיתון הארץ, אפריל –כבר לא מדממים למוות .6

7. Mitchell L, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Gottl U. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost 9:1856-1858, 2011.

8. Ignjatovic V, Kenet G, Monagle P; Perinatal and Pediatric Haemostasis Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Developmental hemostasis: recommendations for laboratories reporting pediatric samples. J Thromb Haemost 10:298-300, 2012.

9. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012;119:1335-1344

10. Carcao MD, van den Berg HM, Ljung R, Mancuso ME; PedNet and the Rodin Study Group. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood 121:3946-52, 2013.

11. Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 121:4046-4055, 2013.

12. Kenet G, Kuperman AA, Brenner B. Author's reply to: Al-Abdi SY. Virus-inactivated plasma and intraventricular hemorrhage in preterm neonates. J Matern Fetal Neonatal Med. 27:1289, 2014.

13. Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R; PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia. 20:747-755, 2014.

14. Kenet G, Nowak-Gottl U. Editorial for special pediatric hemostasis issue BCMD.


27

Blood Cells Mol Dis. 67:1, 2017.

מנדלוביץ' שרינה, -אריה, דרדיק רימה, לוי-דממת בארץ הקודש, התייצגות והתנהלות. ברג אסף .15"הרפואה". הוגש לפרסום, 2018. קנת גילי. ברזני תמי, בשרי דליה,

Member of Editorial Boards 1999 Member of the editorial board of the Hemophilia Forum

2000 Member of the International Hematology Advisory Board of

Novo Nordisk

2002 Cochair - Scientific Subcommittee of ISTH for Pediatric and

Neonatal Thrombosis

2005 Scientific advisory board for the International Congress on

Women’s Issues and Thrombosis, Budapest, Hungary

2006 Scientific advisory board for the 19th International Thrombosis

Congress, Tel-Aviv, Israel

2006 Scientific advisory board of ISTH

2007 Scientific Advisory Board for the International Congress on

Women's Issues and Thrombosis, Vienna, Austria



Women's Issues and Thrombosis, Prague, Czech Republic

2010 Scientific Advisory Board for the WFH



Women's Issues and Thrombosis, Berlin, Germany

2011 Scientific Advisory Board for the PNAS Congress, Padua, Italy

2011 Educational book reviewer, ASH, USA

2012 Scientific Advisory Board for the WFH

2012 Educational book reviewer, ASH, USA


Women's Issues and Thrombosis, Vienna, Austria

2013 Scientific Advisory Board for the EHA, Stockholm, Sweden

2013 Scientific Advisory Board for the ISTH, Amsterdam, NL

2013 Scientific advisory board, ESPHI, Kiel, Germany

2014 Scientific advisory board, MLTD, Valencia, Spain

Educationcme-utilities.com/mailshotcme/IACH/CVs/Kenet CV-reg-Apr2018.pdf · development of new...

Documents

Transcript of Educationcme-utilities.com/mailshotcme/IACH/CVs/Kenet CV-reg-Apr2018.pdf · development of new...